PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer (PAZOFOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02055690

Recruitment Status : Terminated (Safety)

First Posted : February 5, 2014

Last Update Posted : October 29, 2018

Sponsor:

Collaborators:

Novartis

Mateon Therapeutics

East and North Hertfordshire NHS Trust

Information provided by (Responsible Party):

Heather Driscoll, The Christie NHS Foundation Trust

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	November 24, 2017
Actual Study Completion Date :	November 24, 2017

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Morgan RD, Banerjee S, Hall M, Clamp AR, Zhou C, Hasan J, Orbegoso C, Taylor S, Tugwood J, Lyon AR, Dive C, Rustin GJS, Jayson GC. Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. Gynecol Oncol. 2020 Mar;156(3):545-551. doi: 10.1016/j.ygyno.2020.01.005. Epub 2020 Jan 10.

To Top